In This Issue .......................................................................................................................................................... A15
Clinical Connections .................................................................................................................................................. A17

Special Articles
Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White—There Is Some Gray and Black
Roy Fleischmann .................................................................................................................................................... 323
Editorial: Tumor Necrosis Factor Antagonists: Killing Two Birds With One Biologic Stone
Joan M. Bathon, Jon T. Giles, and Daniel H. Solomon ........................................................................................ 326
Editorial: The Innate and Adaptive Immune Response Are Both Involved in Drug-Induced Autoimmunity
Amr H. Sawalha ...................................................................................................................................................... 330
The Science Behind Biosimilars: Entering a New Era of Biologic Therapy
S. Louis Bridges Jr., Douglas W. White, Angus B. Worthing, Ellen M. Gravallese, James R. O’Dell,
Kamala Nola, Jonathan Kay, and Stanley B. Cohen, on behalf of the American College of Rheumatology...... 334
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
Laura C. Coates, Oliver FitzGerald, Joseph F. Merola, Josef Smolen, Leonieke J. J. van Mens,
Heidi Bertheussen, Wolf-Henning Boehncke, Kristina Callis Duffin, Willemina Campbell, Maarten de Wit,
Dafna Gladman, Alice Gottlieb, Jana James, Arthur Kavanaugh, Lars Erik Kristensen, Tore K. Kvien,
Thomas Luger, Neil McHugh, Philip Mease, Peter Nash, Alexis Ogdie, Cheryl F. Rosen, Vibeke Strand,
William Tillett, Douglas J. Veale, and Philip S. Helliwell .................................................................................... 345

Rheumatoid Arthritis
Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
Michael D. Richter, Olga Pinkston, Lisa A. Kottschade, Heidi D. Finnes, Svetomir N. Markovic, and Uma Thanarajasingam.................................................................................................................. 356
CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification
Nishanthi Thalayasingam, Nisha Nair, Andrew J. Skelton, Jonathan Massey, Amy E. Anderson,
Alexander D. Clark, Julie Diboll, Dennis W. Lendrem, Louise N. Reynard, Heather J. Cordell,
Stephen Eyre, John D. Isaacs, Anne Barton, and Arthur G. Pratt .................................................................... 361
Inflammatory Cytokines Stabilize SOXC Transcription Factors to Mediate the Transformation of Fibroblast-Like Synoviocytes in Arthritic Disease
Pallavi Bhattaram, George Muschler, Viktor Wixler, and Véronique Lefebvre .................................................. 371

Osteoarthritis
Cartilage MicroRNA Dysregulation During the Onset and Progression of Mouse Osteoarthritis Is Independent of Aggrecanolysis and Overlaps With Candidates From End-Stage Human Disease
Louise H. W. Kung, Varshini Ravi, Lynn Rowley, Constanza Angelucci, Amanda J. Fosang,
Katrina M. Bell, Christopher B. Little, and John F. Bateman ........................................................................ 383

Psoriatic Arthritis
Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity
Agnes Szentpetery, Gérard M. Healy, Darragh Brady, Muhammad Haroon, Phil Gallagher,
Ciaran E. Redmond, Hannah Fleming, John Duignan, Jonathan D. Dodd, and Oliver FitzGerald ..................... 396
Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease
Lihi Eder, Aditya A. Joshi, Amit K. Dey, Richard Cook, Evan L. Siegel, Dafna D. Gladman, and Nehal N. Mehta ........................................................................................................................................ 408
Systemic Lupus Erythematosus
Sex Differences in Health Care Utilization, End-Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis
Blockade of Treg Cell Differentiation and Function by the Interleukin-21–Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus
Hiroshi Kato and Andras Perl ................................................................................................................................. 427

Vasculitis
18F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis
Peter C. Grayson, Sara Alehashemi, Armin A. Bagheri, Ali Cahid Civelek, Thomas R. Cupps, Mariana J. Kaplan, Ashkan A. Malayeri, Peter A. Merkel, Elaine Novakovich, David A. Bluemke, and Mark A. Ahlman ...................................................... 439

Clinical Images
Etanercept-Induced Lymphocytic Infiltration of Jessner-Kanof
Noémie Abbad, Tristan Lanal, Céline Brenuchon, Gauthier Morel, and Xavier Deprez .............................................. 449

Systemic Sclerosis
Association of Defective Regulation of Autoreactive Interleukin-6–Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis
Taher E. Taher, Voon H. Ong, Jonas Bystrom, Sophie Hillion, Quentin Simon, Christopher P. Denton, Jacques-Olivier Pers, David J. Abraham, and Rizgar A. Mageed ........................................................................................................ 450

Gout
Brief Report: Validation of a Definition of Flare in Patients With Established Gout

Errata
Error in Description of Enzyme Range Calculations in Footnote of Table 3 in the Article by Rider et al (Arthritis Rheumatol, May 2017) ............................................................................................................. 467
Error in Percent Increased SRI-6 Response Rate in Subgroup of Atacicept-Treated Patients Versus Placebo in the Article by Merrill et al (Arthritis Rheumatol, February 2018) .............................................................................. 467

Autoimmunity
Brief Report: Drugs Implicated in Systemic Autoimmunity Modulate Neutrophil Extracellular Trap Formation
Jorge A. Irizarry-Caro, Carmelo Carmona-Rivera, Daniella M. Schwartz, Sami S. Khaznadar, Mariana J. Kaplan, and Peter C. Grayson .............................................................................................................. 468

Letters
Lack of Effect of Teriparatide on Joint Erosions in Rheumatoid Arthritis Is an Expected Result: Comment on the Article by Solomon et al
Giovanni Adami, Maurizio Rossini, Ombretta Viapiana, Angelo Fassio, Luca Idolazzi, Giovanni Orsolini, and Davide Gatti ......................................................................................................................... 475
Reply
Ellen M. Gravallese, Jonathan Kay, Jeffrey Duryea, and Daniel H. Solomon ................................................................ 476

ACR Announcements .................................................................................................................................................. A19

Cover image: The figure on the cover is a 3-dimensional reconstruction image of the aorta and branch arteries from an 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scan in a patient with giant cell arteritis. The image, taken during a period of established clinical remission, depicts severe FDG uptake (red) throughout the large arteries, suggestive of ongoing vascular inflammation. The patient experienced a clinical relapse 4 months after this image was obtained. This issue of Arthritis & Rheumatology features a report describing the use of FDG-PET to monitor vascular information in patients with large vessel vasculitis (Grayson et al, pages 439–449). Image courtesy of Peter C. Grayson, MD, MSc and Mark A. Ahlman, MD.